Low-dose venlafaxine-associated liver toxicity in chronic hepatitis [3]

Annals of Pharmacotherapy

Volumn 38, Issue 2, 2004, Pages 352-353

  Sencan, Irfan ^a   Sahin, Idris ^a   Ozcetin, Adnan ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LIVER ENZYME; VENLAFAXINE;

ADULT; ANAMNESIS; AUTONOMIC DYSFUNCTION; CASE REPORT; CHRONIC HEPATITIS; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS, CHRONIC; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS;

EID: 1642580645     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D205     Document Type: Letter

References (4)

1. Serotonin-norepinephrine reuptake inhibitors. In: Kaplan HI, Sadock BJ, eds. Kaplan and Sadock's synopsis of psychiatry. Giza, Egypt: Mass Publishing Co., 1998:1081-3.
2. Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis (letter). Ann Intern Med 2000;132:417.
3. Horsmans Y, De Clereq M, Sempeux C. Venlafaxine-associated hepatitis (letter). Ann Intern Med 1999;130:944.
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.